The Directory of Pharma Companies and News

Forest Laboratories

Actavis plc and Forest Laboratories, Inc. announced on February 18, 2014 that they have entered into a definitive agreement under which Actavis will acquire Forest for a combination of cash and equity valued at approximately $25 billion. The transaction will create a premier global pharmaceutical leader both in the specialty and primary care arenas. The combination will significantly increase the size of the Actavis Specialty Brands Portfolio to over 30 products principally marketed in the United States, Canada and Europe, and will strengthen the company’s industry-leading pipeline to more than 20 products in various stages of development. We believe we will create a new kind of specialty pharmaceutical company: a specialty pharmaceutical company combining Actavis’ generic DNA with a focus on providing high-quality products efficiently and cost effectively, including an extraordinary array of important specialty branded products, a worldwide portfolio of generic products, OTC products and ultimately biosimilar products to our global customer base. When combined with the expansive 60+ market global commercial powerhouse of Actavis Pharma and the industry-leading manufacturing capabilities of Actavis Global Operations, Actavis and Forest will operate a truly formidable pharmaceutical company – and continue to drive exceptional value for our shareholders, customers and employees. The per share consideration represents a premium of approximately 25 percent per share over Forest's stock price, and a premium of approximately 31 percent over Forest's 10-day volume weighted average stock price, as of the close of trading on February 14, 2014. If successfully completed, the transaction will combine two of the world's fastest-growing specialty pharmaceutical companies, with combined annual revenues of over $15 billion anticipated for 2015.
Category: Pharmaco
Category: Pharmaco

Forest Laboratories News

2014-06-30Actavis and Forest Receive U.S. FTC Clearance for Actavis’ Proposed Acquisition of Forest
2014-06-30Actavis and Forest Announce Preliminary Stockholder Merger Consideration Election Results
2014-06-24Actavis and Forest Announce Tentative Election Deadline of June 27, 2014
2014-06-23Forest Laboratories, Inc. Announces Positive Topline Results from Three Phase III Trials for Vilazodone in the Treatment...
2014-06-23Actavis and Forest Laboratories Announce Appointment of C. David Nicholson, PhD to lead Actavis Global Brands Research a...
2014-06-20Forest Laboratories, Inc. to Present Cariprazine Data at the International College of Neuropsychopharmacology World Cong...
2014-06-18Forest Obtains Six Months U.S. Pediatric Exclusivity for NAMENDA® and NAMENDA XR®
2014-06-17Actavis and Forest Shareholders Approve Proposals Related to Actavis’ Planned Acquisition of Forest
2014-06-12Forest Laboratories, Inc. Announces Receipt of Requisite Consents and Expiration of Consent Solicitations for Certain of...
2014-06-10Forest Laboratories Announces Intention to Continue Marketing Both NAMENDA® TABLETS and Once-Daily NAMENDA XR® Into the ...
1970-01-01Servier announces an increase in turnover for 2015-2016
1970-01-01GeNeuro and Servier announce ANGEL-MS extension clinical study in multiple sclerosis
1970-01-01Mundipharma receives positive European Commission decision on Targin® (oxycodone/naloxone) for the treatment of Restless... (PDF)
1970-01-01New survey reveals asthma continues to disrupt millions of lives across Europe (PDF)
1970-01-01Rachel Gooch, European Commercial Project Manager, Respiratory at Mundipharma, is named European Marketer of the Year (PDF)
Brought to you by - Latest Jobs in Pharma
Brought to you by - Latest Jobs in Pharma.